DK0921812T3 - Insulinpræparater, som indeholder NaCi - Google Patents

Insulinpræparater, som indeholder NaCi

Info

Publication number
DK0921812T3
DK0921812T3 DK97928123T DK97928123T DK0921812T3 DK 0921812 T3 DK0921812 T3 DK 0921812T3 DK 97928123 T DK97928123 T DK 97928123T DK 97928123 T DK97928123 T DK 97928123T DK 0921812 T3 DK0921812 T3 DK 0921812T3
Authority
DK
Denmark
Prior art keywords
insulin preparations
preparations containing
containing nacl
insulin
nacl
Prior art date
Application number
DK97928123T
Other languages
English (en)
Other versions
DK0921812T4 (da
Inventor
Elsebeth Norup
Liselotte Langkjaer
Svend Havelund
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8096378&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0921812(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of DK0921812T3 publication Critical patent/DK0921812T3/da
Publication of DK0921812T4 publication Critical patent/DK0921812T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
DK97928123.5T 1996-06-20 1997-06-19 Insulinpræparater, som indeholder et halogenid DK0921812T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK68596 1996-06-20
PCT/DK1997/000268 WO1997048414A1 (en) 1996-06-20 1997-06-19 INSULIN PREPARATIONS CONTAINING NaCl

Publications (2)

Publication Number Publication Date
DK0921812T3 true DK0921812T3 (da) 2002-02-11
DK0921812T4 DK0921812T4 (da) 2012-04-02

Family

ID=8096378

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97928123.5T DK0921812T4 (da) 1996-06-20 1997-06-19 Insulinpræparater, som indeholder et halogenid

Country Status (21)

Country Link
EP (1) EP0921812B2 (da)
JP (2) JP4404380B2 (da)
KR (1) KR100451778B1 (da)
CN (1) CN1120019C (da)
AT (1) ATE208208T1 (da)
AU (1) AU720484B2 (da)
BR (1) BR9709845B1 (da)
CA (1) CA2258097C (da)
CZ (1) CZ297937B6 (da)
DE (1) DE69708121T3 (da)
DK (1) DK0921812T4 (da)
ES (1) ES2167751T5 (da)
HU (1) HU228094B1 (da)
IL (2) IL127366A0 (da)
NO (1) NO324430B1 (da)
PL (1) PL189964B1 (da)
PT (1) PT921812E (da)
RU (1) RU2182015C2 (da)
UA (1) UA49890C2 (da)
WO (1) WO1997048414A1 (da)
ZA (1) ZA975470B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69924232D1 (de) 1998-01-09 2005-04-21 Novo Nordisk As Stabilisierte insulin-zubereitungen
US6489292B1 (en) 1998-11-18 2002-12-03 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
DE69914934T2 (de) * 1998-11-18 2005-01-05 Novo Nordisk A/S Stabile, wässrige insulin-präparate ohne phenol und cresol
WO2000043034A2 (en) * 1999-01-26 2000-07-27 Eli Lilly And Company Monodisperse hexameric acylated insulin analog formulations
EP1165063A1 (en) * 1999-04-05 2002-01-02 Verteletsky, Pavel Vasilievich Use of succinic acid or salts thereof for the treatment of diabetes mellitus and wound healing
EP1523993A1 (en) * 1999-12-16 2005-04-20 Eli Lilly & Company Polypeptide compositions with improved stability
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
PT1242121E (pt) * 1999-12-16 2005-05-31 Lilly Co Eli Composicoes polipeptidicas com estabilidade melhorada
EP2926828B1 (en) 2004-10-05 2019-12-11 Novo Nordisk A/S A pharmaceutical formulation
HUE037449T2 (hu) 2008-10-17 2018-08-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
AR080669A1 (es) 2009-11-13 2012-05-02 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina
WO2011058082A1 (de) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten und methionin
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
BR112014004726A2 (pt) 2011-08-29 2017-04-04 Sanofi Aventis Deutschland combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2014102623A1 (en) 2012-12-26 2014-07-03 Wockhardt Limited Pharmaceutical composition
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
CN105899190B (zh) * 2014-01-09 2022-06-14 赛诺菲 门冬胰岛素的稳定化药物制剂
AU2015205624A1 (en) 2014-01-09 2016-07-14 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
JP2020143105A (ja) * 2014-01-09 2020-09-10 サノフイＳａｎｏｆｉ インスリンアスパルトの安定化された医薬製剤
JP2020114861A (ja) * 2014-01-09 2020-07-30 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
SG11201604708VA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
PL3229828T3 (pl) 2014-12-12 2023-07-31 Sanofi-Aventis Deutschland Gmbh Formulacja o ustalonym stosunku insuliny glargine/liksysenatydu
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK116527B (da) * 1967-03-01 1970-01-19 Nordisk Insulinlab Fremgangsmåde til fremstilling af en hurtigtvirkende, holdbar, neutral opløsning af rent krystallinsk okseinsulin eller okseinsulin, der ved tilsætning af Zn er krystalliserbart i vand, eller blandinger af okseinsulin og insulin af anden oprindelse.
US4783441A (en) † 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
US4439181A (en) * 1981-01-26 1984-03-27 Regents Of The University Of Minnesota Polyol-hormone mixture for use in chronic parenteral hormone administration
AU550068B2 (en) † 1981-03-10 1986-02-27 Novo Nordisk A/S Zinc insulin stabilized with calcium or magnesium salts
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
NZ232375A (en) * 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
EP0705275B1 (en) * 1993-06-21 1999-02-03 Novo Nordisk A/S Asp-b28 insulin crystals
HU217684B (hu) * 1993-09-17 2000-03-28 Novo Nordisk A/S Acilezett inzulinszármazékok és azokat tartalmazó gyógyszerkészítmények és előállításuk
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations

Also Published As

Publication number Publication date
PT921812E (pt) 2002-04-29
DE69708121T3 (de) 2012-05-16
HUP9904031A3 (en) 2000-10-30
CA2258097A1 (en) 1997-12-24
JP2000513344A (ja) 2000-10-10
CN1120019C (zh) 2003-09-03
NO324430B1 (no) 2007-10-15
WO1997048414A1 (en) 1997-12-24
PL189964B1 (pl) 2005-10-31
EP0921812A1 (en) 1999-06-16
DK0921812T4 (da) 2012-04-02
EP0921812B1 (en) 2001-11-07
HUP9904031A2 (hu) 2000-04-28
IL127366A (en) 2007-07-04
NO985981L (no) 1998-12-18
KR100451778B1 (ko) 2004-11-16
AU720484B2 (en) 2000-06-01
BR9709845B1 (pt) 2008-11-18
BR9709845A (pt) 1999-08-10
ATE208208T1 (de) 2001-11-15
UA49890C2 (uk) 2002-10-15
CZ395698A3 (cs) 1999-05-12
DE69708121T2 (de) 2002-08-01
ES2167751T5 (es) 2012-03-30
RU2182015C2 (ru) 2002-05-10
CN1222083A (zh) 1999-07-07
ZA975470B (en) 1997-12-22
JP4404380B2 (ja) 2010-01-27
CA2258097C (en) 2011-02-08
NO985981D0 (no) 1998-12-18
CZ297937B6 (cs) 2007-05-02
KR20000022031A (ko) 2000-04-25
EP0921812B2 (en) 2011-12-21
ES2167751T3 (es) 2002-05-16
HU228094B1 (en) 2012-10-29
IL127366A0 (en) 1999-10-28
JP2009235075A (ja) 2009-10-15
AU3253697A (en) 1998-01-07
DE69708121D1 (de) 2001-12-13
PL330763A1 (en) 1999-05-24

Similar Documents

Publication Publication Date Title
DK0921812T3 (da) Insulinpræparater, som indeholder NaCi
DK0428038T3 (da) Transdermal administration af 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
ATE270557T1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
DK0812198T3 (da) Stabilisering af prostaglandinpræparater
PT758248E (pt) Formulacoes para o factor ix
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
FI925615A0 (fi) Stabiliserade farmaceutiska kompositioner, som innehaoller en hmg-coa-reduktas-inhibitorfoerening
DK1172114T3 (da) Stabile koncentrerede insulinpræparater til pulmonær indgivelse
DE69737995D1 (de) INSULINPREPARATION MIT MAnnitol
ATE231872T1 (de) Thiazolopyrimidinderivate
ID24520A (id) Analog-analog peptida lh-rh, penggunaannya dan komposisi farmasi yamg mengandungnya
NO995831D0 (no) Injiserbar, klar formulering av et anestetisk middel
ES2071663T3 (es) Analogo de fluoxetina.
IS5366A (is) Notkun á fankínóni til meðhöndlunar á Alzheimers-sjúkdómi
ES2152315T3 (es) Xamoneline tartrato.
ATE196914T1 (de) Lh-rh analoge mit starrer konformation, deren verwendungen und pharmazeutische zusammensetzungen
DK0626173T3 (da) Aerosolpræparat indeholdende fusafungin
ATE204286T1 (de) Modifizierte alpha-d-glcp-(1,2)-alpha-d-glcp-(1, 3)-alpha-d-glcp-analoge
FI954401A0 (fi) Atseotrooppimaiset koostumukset, joissa on 1,1,1,2,3,3,3-heptafluoripropaania ja 1,1-difluorietaania
ATE101194T1 (de) Azeotropaehnliche zusammensetzungen von 1,3dichlor-1,1,2,2,3-pentafluorpropan und 2-methyl-2-propanol.